More than half of adolescents treated with baricitinib achieved complete or near-complete scalp hair regrowth at 1 year, with ...

Fifty-four percent of patients ages 12 to 18 with severe alopecia noticed hair regrowth when given 4-mg of Olumiant (oral baricitinib), according to results of a study presented this week at the 2025 ...

The alopecia areata market is projected to grow significantly in the seven major markets, driven by an expanding pipeline with diverse mechanisms of action, including JAK inhibitors and IL-2 T ...

Notably, in a post-hoc analysis which included adolescents who were diagnosed with severe AA less than 2 years before starting treatment, successful hair regrowth at 1 year was achieved in 80% and ...

Glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely prescribed for Type 2 diabetes and obesity owing to their ...

In a separate, post-hoc analysis of adolescent patients who had been diagnosed with severe AA less than two years before starting treatment, 80% of those receiving baricitinib 4 mg and 64.3% receiving ...

"Lilly and Incyte to seek approval of alopecia JAK inhibitor in children" was originally created and published by Clinical ...

When Keira was diagnosed with alopecia areata at just 2 years old, her mother, Leslie, felt lost and unsure where to turn for support. "It was so isolating and lonely," said Leslie. "I felt desperate ...

PARIS — Long-term results from the ALLEGRO clinical trial program of Pfizer’s JAK inhibitor ritlecitinib for severe alopecia areata showed that complete scalp regrowth occurred in a good proportion of ...

When a teenager starts losing their hair, the world often rushes to offer reassurances: "It's just hair." But for the nearly 7 million people in the U.S. living with alopecia areata, many of whom are ...